Cargando…

Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?

PURPOSE: To evaluate the clinical utility, diagnostic yield and rationale of integrating microarray analysis in the clinical diagnosis of hematological malignancies in comparison with classical chromosome karyotyping/fluorescence in situ hybridization (FISH). METHODS: G-banded chromosome analysis, F...

Descripción completa

Detalles Bibliográficos
Autores principales: Peterson, Jess F., Aggarwal, Nidhi, Smith, Clayton A., Gollin, Susanne M., Surti, Urvashi, Rajkovic, Aleksandar, Swerdlow, Steven H., Yatsenko, Svetlana A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662459/
https://www.ncbi.nlm.nih.gov/pubmed/26299921
_version_ 1782403159331700736
author Peterson, Jess F.
Aggarwal, Nidhi
Smith, Clayton A.
Gollin, Susanne M.
Surti, Urvashi
Rajkovic, Aleksandar
Swerdlow, Steven H.
Yatsenko, Svetlana A.
author_facet Peterson, Jess F.
Aggarwal, Nidhi
Smith, Clayton A.
Gollin, Susanne M.
Surti, Urvashi
Rajkovic, Aleksandar
Swerdlow, Steven H.
Yatsenko, Svetlana A.
author_sort Peterson, Jess F.
collection PubMed
description PURPOSE: To evaluate the clinical utility, diagnostic yield and rationale of integrating microarray analysis in the clinical diagnosis of hematological malignancies in comparison with classical chromosome karyotyping/fluorescence in situ hybridization (FISH). METHODS: G-banded chromosome analysis, FISH and microarray studies using customized CGH and CGH+SNP designs were performed on 27 samples from patients with hematological malignancies. A comprehensive comparison of the results obtained by three methods was conducted to evaluate benefits and limitations of these techniques for clinical diagnosis. RESULTS: Overall, 89.7% of chromosomal abnormalities identified by karyotyping/FISH studies were also detectable by microarray. Among 183 acquired copy number alterations (CNAs) identified by microarray, 94 were additional findings revealed in 14 cases (52%), and at least 30% of CNAs were in genomic regions of diagnostic/prognostic significance. Approximately 30% of novel alterations detected by microarray were >20 Mb in size. Balanced abnormalities were not detected by microarray; however, of the 19 apparently “balanced” rearrangements, 55% (6/11) of recurrent and 13% (1/8) of non-recurrent translocations had alterations at the breakpoints discovered by microarray. CONCLUSION: Microarray technology enables accurate, cost-effective and time-efficient whole-genome analysis at a resolution significantly higher than that of conventional karyotyping and FISH. Array-CGH showed advantage in identification of cryptic imbalances and detection of clonal aberrations in population of non-dividing cancer cells and samples with poor chromosome morphology. The integration of microarray analysis into the cytogenetic diagnosis of hematologic malignancies has the potential to improve patient management by providing clinicians with additional disease specific and potentially clinically actionable genomic alterations.
format Online
Article
Text
id pubmed-4662459
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-46624592015-12-02 Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? Peterson, Jess F. Aggarwal, Nidhi Smith, Clayton A. Gollin, Susanne M. Surti, Urvashi Rajkovic, Aleksandar Swerdlow, Steven H. Yatsenko, Svetlana A. Oncotarget Research Paper: Chromosome PURPOSE: To evaluate the clinical utility, diagnostic yield and rationale of integrating microarray analysis in the clinical diagnosis of hematological malignancies in comparison with classical chromosome karyotyping/fluorescence in situ hybridization (FISH). METHODS: G-banded chromosome analysis, FISH and microarray studies using customized CGH and CGH+SNP designs were performed on 27 samples from patients with hematological malignancies. A comprehensive comparison of the results obtained by three methods was conducted to evaluate benefits and limitations of these techniques for clinical diagnosis. RESULTS: Overall, 89.7% of chromosomal abnormalities identified by karyotyping/FISH studies were also detectable by microarray. Among 183 acquired copy number alterations (CNAs) identified by microarray, 94 were additional findings revealed in 14 cases (52%), and at least 30% of CNAs were in genomic regions of diagnostic/prognostic significance. Approximately 30% of novel alterations detected by microarray were >20 Mb in size. Balanced abnormalities were not detected by microarray; however, of the 19 apparently “balanced” rearrangements, 55% (6/11) of recurrent and 13% (1/8) of non-recurrent translocations had alterations at the breakpoints discovered by microarray. CONCLUSION: Microarray technology enables accurate, cost-effective and time-efficient whole-genome analysis at a resolution significantly higher than that of conventional karyotyping and FISH. Array-CGH showed advantage in identification of cryptic imbalances and detection of clonal aberrations in population of non-dividing cancer cells and samples with poor chromosome morphology. The integration of microarray analysis into the cytogenetic diagnosis of hematologic malignancies has the potential to improve patient management by providing clinicians with additional disease specific and potentially clinically actionable genomic alterations. Impact Journals LLC 2015-07-31 /pmc/articles/PMC4662459/ /pubmed/26299921 Text en Copyright: © 2015 Peterson et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper: Chromosome
Peterson, Jess F.
Aggarwal, Nidhi
Smith, Clayton A.
Gollin, Susanne M.
Surti, Urvashi
Rajkovic, Aleksandar
Swerdlow, Steven H.
Yatsenko, Svetlana A.
Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
title Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
title_full Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
title_fullStr Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
title_full_unstemmed Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
title_short Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
title_sort integration of microarray analysis into the clinical diagnosis of hematological malignancies: how much can we improve cytogenetic testing?
topic Research Paper: Chromosome
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662459/
https://www.ncbi.nlm.nih.gov/pubmed/26299921
work_keys_str_mv AT petersonjessf integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting
AT aggarwalnidhi integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting
AT smithclaytona integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting
AT gollinsusannem integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting
AT surtiurvashi integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting
AT rajkovicaleksandar integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting
AT swerdlowstevenh integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting
AT yatsenkosvetlanaa integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting